Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non–small-cell lung cancer-Reference-Cited by-同舟云学术

Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non–small-cell lung cancer

Published:2018-06-26 Issue:1 Volume:8 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Chen Jin-Hua,Yang Jia-Lian,Chou Che-Yi^ORCID,Wang Jiun-Yi,Hung Chin-Chuan

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-018-27994-x.pdf

Reference78 articles.

1. Ettinger, D. S. et al. Non-small cell lung cancer, version 2.2013. Journal of the National Comprehensive Cancer Network: JNCCN 11, 645–653; quiz653 (2013).

2. Cetin, K., Ettinger, D. S., Hei, Y. J. & O’Malley, C. D. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. Clinical epidemiology 3, 139–148, https://doi.org/10.2147/clep.s17191 (2011).

3. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England journal of medicine 363, 1693–1703, https://doi.org/10.1056/NEJMoa1006448 (2010).

4. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England journal of medicine 350, 2129–2139, https://doi.org/10.1056/NEJMoa040938 (2004).

5. Bazhenova, L. et al. An international, multicenter, randomized, double-blind phase III study of maintenance belagenpumatucel-l in non-small cell lung cancer (NSCLC): Updated analysis of patients enrolled within 12 weeks of completion of chemotherapy. Journal of Clinical Oncology 32 (2014).

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simvastatin Enhanced Anti-tumor Effects of Bevacizumab against Lung Adenocarcinoma A549 Cells via Abating HIF-1α-Wnt/β-Catenin Signaling Pathway;Anti-Cancer Agents in Medicinal Chemistry;2023-11

3. Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy;BMC Cancer;2023-01-21

4. What is the importance of difference in LCM strategy in drug development? – Learnings from Keytruda and Opdivo;Drug Discovery Today;2022-12

5. Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small-cell lung cancer: a network meta-analysis;Future Oncology;2022-04